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Abstract 
Objective: Cannabis consumption during adolescence has been reported as a 
risk-factor for psychotic-like experiences (PLEs) and schizophrenia. However, brain 
developmental processes associated with cannabis-related PLEs are still ill-described. 
Method: 706 adolescents from the general population that were recruited by the 
IMAGEN consortium had structural MRI scans both at 14 and 19 years-old. We used 
deformation-based morphometry to map voxel-wise brain changes between the two 
time points, using the pairwise algorithm in SPM12b. We used an a-priori region of 
interest (ROI) approach focusing on the hippocampus/parahippocampus to perform 
voxel-wise linear regressions. Life time cannabis consumption was assessed using the 
European School Survey Project on Alcohol and other Drugs (ESPAD) and PLEs 
were assessed with the Comprehensive Assessment Psychotic-like experiences 
(CAPE). We first tested whether hippocampus/para-hippocampus development was 
associated with PLEs. Then, we formulated and tested an a-priori simple mediation 
model where uncus development mediates the association between lifetime cannabis 
consumption and PLEs.  
Results: We found that PLEs was associated with reduced expansion within a specific 
region of the right hippocampus/para-hippocampus formation, the uncus (p=0.002 at 
the cluster level, p=0.018 at the peak-level). The partial simple mediation model 
revealed a significant total effect from lifetime cannabis consumption to PLEs 
(b=0.069 95CI [0.04-0.1], p=2 x 10-16), as well as a small yet significant, indirect 
effect of right uncus development (0.004, 95IC [0.0004-0.01], p=0.026). 
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Conclusion: We show here that the uncus development is involved in the cerebral 
basis of PLEs in a population-based sample of healthy adolescents.     
Key words: cannabis, psychotic-like experiences (PLEs), uncus, paired designed 
MRI, deformation-based morphometry  
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Introduction  
Psychosis can be perceived as a continuum ranging from non-help-seeking 
individuals among the general population with psychotic-like experiences (PLEs), to 
help-seeking people with ultra-high risk of psychosis, to first episode psychosis and 
patients with chronic psychotic disorder.1 The median prevalence of PLEs amounts to 
5~8% in general population2 and they usually emerge during late adolescence. PLEs 
represent a non-clinical psychosis phenotype, but carry an increased risk to develop 
schizophrenia-spectrum disorder.3, 4 Another widely known risk factor for 
schizophrenia development is cannabis consumption which has been identified both in 
epidemiological surveys and prospective birth cohort studies.5, 6 Cannabis is suggested 
to cause the development of schizophrenia because previous studies have shown that 
cannabis intoxication can induce acute psychosis7 and the administration of 
tetrahydrocannabinol is responsible for acute psychotic symptoms in healthy 
volunteers 8 and the cannabis/psychosis association follows a dose response effect.9 
On another hand, strong evidence points to hippocampal/parahippocampus,  
atrophy both in patients with chronic psychotic disorder,10 first episode patients11 and 
ultra-high risk individuals for psychosis.12 Similarly, some (but not all)13 investigators 
reported association of chronic cannabis use with decreased cortical volume, 
including the hippocampus/parahippocampus,14 which is a region known to have high 
cannabis receptor 1 (CB1) density.15 The uncus, a subregion of the 
hippocampus/parahippocampus formation, has been associated with both positive 
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(hallucination) and negative (social withdrawal) psychotic symptoms4 and might also 
be involved in cannabis-associated psychotic-like experiences.  
Furthermore, animal models of cannabis intoxication also found hippocampal 
atrophy, suggesting a causal relation between cannabis intake and specific structural 
brain abnormalities. Thus, hippocampus atrophy seems to be both associated with 
psychosis (which is strongly related to cannabis intake ) and by cannabis intake itself.    
While a recent study adopted a longitudinal approach to detect hippocampal 
atrophy among heavy young adult cannabis users in the hippocampus formation,16 it 
did not integrate any information about the PLEs. Thus, the relation between 
developmental changes in the hippocampal formation during adolescence, cannabis 
use and PLEs is unclear. 
We therefore adopted a paired designed MRI deformation-based morphometry 
analysis to investigate the association between brain volume development (from 14 
years to 19 years) with PLEs and cannabis use in the IMAGEN sample of healthy 
adolescents. First, we determined whether longitudinal changes of grey matter (GM) 
within the hippocampus formation were associated with PLEs, using a 
literature-based region of interest approach. Then we formulated and tested one model 
where cannabis intake would be directly associated with PLEs, and hippocampus 
volumetric changes would partially mediate this association. 
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Method 
Subjects: The subjects were selected from the IMAGEN project, a European 
multi-center neuroimaging genetic study of adolescent participants17 recruited from 
eight research centers across Europe. In the present study, we used data from baseline 
(BL, age 14, n=780) and follow-up (FU, age 19, total n=780), where paired structural 
MRI images were available (https://imagen-europe.com/). After quality control of 
both the MRI images and behavior data, 706 subjects were included in the final 
analyses (see Figure S1, available online). Subjects with psychiatric disorders were 
excluded from the IMAGEN project at BL because it aims at identifying genetic, 
cerebral and behavioural markers of mental disorders which appears during 
adolescence, including addiction. The study was approved by the local ethics 
committees and adhered to the Declaration of Helsinki. An overview of demographic 
information for all subjects is shown in Table 1. 
 
Psychotic-like experiences: PLEs in the general population were assessed by 
the self-report Community Assessment of Psychic Experiences (CAPE)18 at FU. The 
questionnaire consists of 42 items covering three symptom dimensions: positive, 
negative and depressive dimensions. It includes 20 questions for positive symptoms, 
14 for negative symptoms, and 8 for depressive symptoms. The subjects were asked 
to rate the frequency of lifetime PLEs on a 4-point Likert scale of ‘Never’, 
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’Sometimes’, ’Often’ and ‘Nearly Always’. The total score was obtained by 
calculating the mean of the 42 items. 
 
Drugs Use: European School Survey Project on Alcohol and Drugs (ESPAD) was 
used to measure the frequency of cannabis, alcohol, cigarette and other illicit drugs 
use in one’s lifetime, past 12 months, past 30 days and past week.  
Lifetime cannabis use was assessed by the question: “How many times in your life 
have you used marijuana or hash?” at 19 years (FU). The answer was scored between 
0~6 according to their use frequencies: 0 = “never”, 1 = “once or twice”, 2 = “3-5 
times”, 3 = “6-9 times”, 4 = “10-19 times”, 5 = “20-39 times”, 6 = “40 times or 
more”. Other drug uses were scored the same way. We also assessed cannabis use at 
14 years (BL) using lifetime cannabis use acquired at 14 years. The frequencies of 
cannabis use at both BL and FU are listed in the supplementary materials (see Table 
S1, available online). 
 
Images Acquisition: Details of the structural MRI acquisition protocols and 
quality controls have been provided elsewhere.17 Briefly, the high-resolution isotropic 
anatomical MRI images (voxels size=1mm3) were obtained using a three-dimensional 
T1-weighted magnetization-prepared gradient-echo sequence (MPRAGE) based on 
the ADNI protocol (details at 
http://adni.loni.usc.edu/methods/documents/mri-protocols/ ).    
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Quality Control: Details of standard operation procedure for the baseline and follow 
up structural MRI quality control can be seen in the supplementary materials 
(Supplement 1, available online).  
 
Baseline MRI data using standard VBM protocol:  We used the standard VBM8 
protocol for preprocessing the BL structural data (14). Briefly, all images were 
spatially normalized to the standard MNI T1 MRI template, segmented into GM, WM 
and cerebrospinal fluid compartments using MNI priors. The segmented images were 
modulated by the Jacobian determinants in order to compensate for the possible 
volume changes during the non-linear spatial normalization procedure. Finally, these 
GM images were smoothing using an 4mm full width at half maximum (FWHM) 
isotropic Gaussian kernel.  
Pairwise analysis of MRI 
This followed 5 sequential steps. First, the SPM12b pairwise tool estimates 
voxel-wise quantitative measures of expansion and volume reduction over time using 
a within-subject template in the native space. Then, the native space within-subject 
template were then segmented using the VBM8 toolbox 
(http://www.neuro.uni-jena.de/vbm/). Here, the segmentation process was data-driven 
and unsupervised and did not require a priori tissue probability maps information.19 
This approach has been found to be effective to segment pediatric structural MRI.20 
Third, we used DARTEL to derive a between subject study-specific template, to 
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which the voxel-wise maps of brain development are registered and normalized to. 
The use of both data-driven segmentation with DARTEL approaches is similar to the 
Template-o-Matic toolbox to build non-adult templates and has been proven to be 
efficient to build early adulthood templates.21 
Given that we focused on the hippocampus/para-hippocampus, we chose to 
smooth the registered and normalized maps of brain development with a kernel of 
4mm FWHM. Full description of the procedure along with the quality control is 
detailed in the supplementary materials (Supplement 2, available online). 
To investigate the association between GM volumetric changes in 
hippocampus/para-hippocampus and PLEs, we firstly created a mask in these areas 
using Wake Forest University (WFU) PickAtlas in SPM12b 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). The mean value of grey matter 
change within the significant cluster was extracted using MarsBar 
(http://marsbar.sourceforge.net/). 
 
Statistical analysis   
Voxel-wise analyses within the hippocampus/para-hippocampus 
We ran voxel-wise multiple linear regression models in SPM12b (see Supplement 3, 
available online): dependent variable was the rate of GM volume changes; 
independent variable was CAPE total score at FU; covariates included gender, age, 
site (dummy-coded), as well as TIV at BL following the latest recommendations 
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about nuisances variables in VBM studies.22 Similarly, we tested for associations 
between BL grey matter volume in the hippocampus/parahippocampus formation and 
CAPE scores, cannabis use at 14 years and 19 years with the same covariates. 
All voxel wise statistics were corrected using the family-wise error (FWE) correction 
for multiple comparisons over the mask in the hippocampus/parahippocampus and 
considered to be significant for p<0.05 after the FWE correction (approximately 32 
000 tests were run). 
Mediation analyses 
The mediation analysis was performed on data from 706 subjects in which all 
mediation variables and covariates were available: GM volumetric changes in the 
right uncus, life time cannabis use and PLEs (Figure 1), using the “mediation” R 
package.23 Based on literature-based arguments of cannabis-induced PLEs and 
hippocampal/parahippocampal atrophy, we formulate the partial simple mediation 
model where cannabis would be associated with PLEs and that association would be 
mediated by right uncus development. Within that model, the direct effect means the 
effect of cannabis use on PLEs when the mediating variable (uncus volume change) is 
not included. The indirect effect means the effect of cannabis use on PLEs through the 
mediating variable. The total effect equals the sum of direct and indirect effects. The 
graphical model is displayed on Figure 1. The covariates included in the mediation 
analyses were the same as in the voxel-wise analyses (i.e. gender, age, site, TIV at 
BL, lifetime alcohol and psycho-analeptic drugs). The correlation matrix between 
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psycho-analeptic drugs and psychotic-like experiences were shown at supplementary 
Table S2, available online. Given the multisite design of the IMAGEN project, we 
used hierarchical linear modelling to model a one-level random intercept for the 
variable “site”, using “lme4” package in R.24 The full code is detailed in the 
supplementary materials (see Supplement 4, available online). 
As post-hoc analyses, we sought for an interaction between gender and cannabis 
consumption on brain development. Moreover, we explored how cannabis 
consumption were associated with the CAPE subscales scores (see Figure S2, 
available online). 
 
Results 
Demographic Characteristics  
The demographic characteristics of subjects at BL and FU are shown in Table 1. 
Seven hundred and six subjects were included in which paired design MRI image, 
CAPE and ESPAD scores were available. The average age at BL was 14.41 years, 
and 18.88 years old at FU. The percentage of cannabis users who had tried cannabis at 
least once in their lifetime increased from 5.0% at BL to 46.50% at FU. The overall 
average score of CAPE at FU was 4.60±0.89, and the scores for CAPE subscales are 
shown in Table 1.   
Voxel-wise analyses 
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We found significant negative correlations between GM volumetric changes and 
CAPE total score in the right uncus ([18，0，-32], cluster size=112 voxels, p=0.020 
FWE correction for cluster level, and p=0.018 FEW corrected at the peak-level), 
suggesting that higher CAPE total score is related to a smaller expansion in the right 
uncus (Figure 2).  
 
Mediation analyses 
As illustrated on Figure 1, we found a significant positive total effect of lifetime 
cannabis intake on PLEs (b=0.069 95CI [0.04-0.1], p=2 x 10-16). We found a positive 
significant direct effect of cannabis intake on PLEs (b=0.064, 95IC [0.03-0.1], p=2 x 
10-16) and an indirect effect of cannabis intake on PLEs mediated by uncus 
development (0.004, 95IC [0.0004-0.01], p=0.026), suggesting partial mediation. Six 
percent of the total effect was mediated by uncus development (95IC [0.006-0.17], 
p=0.03). The graphical model is displayed on Figure 1. While cannabis consumption 
was negatively associated with development of the uncus (i.e. reduced expansion over 
time) in the whole sample (t(1,617) = -2.3, p=0.02), we did not find any interaction 
between gender and cannabis intake on uncus development, with cannabis being 
associated with reduced expansion of uncus in both genders (see Figure S3, available 
online). The detailed associations between cannabis intake and cape sub-scores are 
provided in supplementary material (see Figure S2, available online). 
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Discussion  
We found that a smaller expansion in the right uncus is associated with greater 
psychotic like experiences. We also found that uncus development partially mediates 
(6%) the relation between lifetime cannabis use and psychotic like experiences.   
The uncus is located at the junction of hippocampus, amygdala and olfactory 
lobe, and is involved in olfactory hallucination, memory impairments and social 
withdrawal.25 Several cross-sectional and longitudinal MRI studies demonstrated 
structural abnormalities in hippocampus formation or uncus among individuals with 
ultra-high risk (UHR) for psychosis12. Functional MRI studies also noted that UHR 
individuals showed less activation than controls in the parahippocampal gyrus, medial 
frontal gyrus during the encoding process of memory task.26, 27 
Our results are consistent with previous research findings in community samples of 
adolescents and young adults showing that lifetime cannabis use was significantly 
correlated with PLEs both in cross-sectional28 and longitudinal samples.29 According 
to our results, a smaller volume increase of the uncus might be one of the 
pathophysiological mechanism mediating the link between cannabis consumption and 
psychotic-like experience. This view is supported by multiple evidence: First, CB1 is 
mainly expressed in the olfactory lobe, hippocampus, parahippocampus and amygdala 
regions.30 Second, animal studies have shown that pubertal exposure to cannabis 
could induced psychotic-like behaviors and hippocampal structures changes such as 
decreased density and increased glial cell reactivity.31 Third, functional and structural 
cross-sectional neuroimaging studies report an association of hippocampal atrophy 
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hippocampus with long-term cannabis use.32 We found volumetric changes on the 
right uncus while previous studies reported on the bilateral side related to 
schizophrenia.33 This discrepancy might be explained by the different stages of the 
continuum hypothesis of psychosis, which might involve different hippocampus 
alterations. In agreement with this hypothesis, previous results found atrophy only in 
the right hippocampus in a homogeneous sample of at-risk individuals who did not 
transition into schizophrenia whereas atrophy within the left hippocampus was 
significant within the group who transitioned into schizophrenia.34 This is consistent 
with our results of smaller expansion of uncus development in the right uncus in 
cannabis associated psychotic like experiences in healthy adolescents. 
The CAPE is a promising tool for the measurement of PLEs in the general 
population. It was reported as a valid, simple and cost-effective screening tool for 
detecting individuals at potential risk for psychosis18. In addition, the CAPE has a 
good prognostic reliability since its scores at baseline could predict schizotypic 
disorders and psychiatric symptoms severity at follow-up in a large longitudinal 
cohort followed during 7.7 months.35 In our study, we found the mean total score of 
CAPE was 4.6 and subscores for positive, negative and depressive symptoms were 
1.3, 1.6 and 1.7, respectively, which were similar to other studies in healthy 
population.18, 35 For the CAPE assessment, we only calculated the frequency but not 
distress of each item, since there was highly correlation (r=0.89, p<0.001) between 
frequency and distress. Previous results suggest that early cannabis use (i.e. before 
age 14 years) is associated with psychotic like experiences36 which we cannot find 
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here. In contrary to Gastel at al.,36 only few individuals had cannabis in our sample 
(see Table S1, available online), which might explain this discrepant result. 
Some limitations must be borne in mind when interpreting these results: first, it 
must be pointed out that our findings conclude to only 6% of the total effect is 
mediated by uncus development. This first suggests that our results warrant 
replication. It also suggests that other pathophysiological mechanisms underlie the 
association between cannabis consumption and PLEs. Previous results showed that 
cannabis-related psychotic symptoms are associated with abnormal pattern of 
pre-fronto-striatal connectivity during an odd-ball paradigm.37 Decreased fractional 
anisotropy (a measure of white matter integrity) has been found in a diffuse network 
including the superior and inferior longitudinal fasciculus, which is later associated 
with the onset of psychosis38. Finally, cannabis consumption in ultra high-risk 
individuals is associated with increased resting state connectivity between the 
thalamus and sensori-motor regions.39 Using the IMAGEN cohort, it has been shown 
that polygenic risk score for schizophrenia moderates the association between 
cannabis consumption and cortical thickness development in boys.40 Having these 
results in mind, further studies might focus on the uncus resting state connectivity 
pattern, and model genetic vulnerability to schizophrenia, to more extensively 
apprehend cannabis-related psychotic like experiences in healthy adolescents.4, 37, 38 
Psychotic like experiences at BL (14 years-old) were not assessed, and conclusions 
about causality cannot be clearly drawn. However, individuals who suffered psychotic 
diseases at BL through DSM-IV-RT diagnostic criteria were excluded. In addition, 
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this study only investigated healthy adolescents with PLEs, and only 15%-25% of 
normal subjects with self-reported PLEs subsequently develop psychotic disorders.41 
Further follow-up studies may establish if changes in uncus volume between 14 and 
19 years old will subsequently be associated with onset of psychosis in the same 
cohort17. It should be noted however that individuals with genetic burden for 
schizophrenia might show higher cannabis consumption and that the causal relations 
between cannabis intake and onset of schizophrenia is, for a small number reversed.  
Other packages are available to adequately segment hippocampus and 
parahippocampus with a longitudinal design42 with recently improved hippocampus 
parcellation.43 However, these non-voxel wise approaches are highly valuable when 
the datasets have more than 2 time points with unbalanced time interval between the 
scans.42 We took advantage of the 2 time points but well-balanced design of 
IMAGEN (all scans acquired at 14 and 19 years-old), to increase resolution and to 
perform voxel-wise analysis. Although we did not have any a-priori hypothesis on the 
uncus, it is embedded in the parahippocampus gyrus42 and using a raw parcellation 
might have increased type 2 errors by meaning the effect across the parahippocampus 
gyrus. Further studies might focus on the uncus and total hippocampal volume might 
be a covariate of interest, in addition to TIV, to test for its association with 
psychotic-like experiences above and beyond the other regions of the hippocampus. 
Fifth, the voxel-wise analyses did not model the hierarchical design of the IMAGEN 
project (i.e. multisite). However, the negative association between PLEs and the 
uncus development in the resulting cluster remained significant while accounting for 
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the one-level random intercept for “site” (t(1,697) = -3.2, p=0.002) and the two models 
(i.e. linear and hierarchical) were not statistically different (χ2=6, p=0.2). Finally, we 
only controlled for alcohol and psycho-analeptic drug use in the present study and one 
cannot rule out that a combination of different drug use might affect the association 
between cannabis and psychotic-like experience. 
Despite these limitations, our results show here that the uncus development is 
involved in the cerebral basis of PLEs and mediates a small, yet significant, 
proportion of the cannabis-associated PLEs in normal adolescents. When interpreted 
in line with the cerebral basis of schizophrenia and emerging psychosis, these results 
are additional arguments for the continuum hypothesis of psychosis from PLEs, to 
UHR, to first episode psychosis and finally to chronic psychotic disorders. 
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TABLE 1. Demographic Characteristics of Subjects at Baseline (BL) and 
Follow-up (FU) 
Characteristics BL(n=706) FU(n=706) 
Mean SD Mean SD 
Age in days  5259.68 338.80 6895.50 241.42 
CAPE Scores     
  Total Score - - 4.602 0.890  
  Positive Symptom - - 1.296 0.209  
  Negative Symptom - - 1.595 0.394  
  Depressive Symptom - - 1.712 0.435  
  n % n % 
Gender     
  Male participants 312 44.20  312 44.20  
  Female participants 394 55.80  394 55.80  
Site     
  London 104 14.70  104 14.70  
  Nottingham 130 18.40  130 18.40  
  Dublin 47 6.70  47 6.70  
  Berlin 85 12.00  85 12.00  
  Hamburg 77 10.90  77 10.90  
  Mannheim 79 11.20  79 11.20  
  Paris 71 10.10  71 10.10  
  Dresden 113 16.00  113 16.00  
Drugs Use    
  Cannabis 34 5.00  328 46.50  
  Alcohol 548 77.60  691 97.90  
  Cigarette 202 28.60  474 67.10  
  Ketamine 0 0.00  22 3.10  
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  LSD 1 0.10  16 2.30  
  Amphetamine 2 0.30  37 5.20  
Note: CAPE=Community Assessment of Psychic Experiences; ESPAD=European 
School Survey Project on Alcohol and Other Drugs. 
 
 
 
FIGURE 1. Reduced Expansion of Uncus Mediates the Association Between 
Cannabis Consumption and Psychotic-Like Experiences: A Mediation Model 
Note: PLE = psychotic-like experiences.  
 
FIGURE 2. Psychotic-Like Experiences are Associated With Reduced Expansion of 
Right Uncus Between 14 and 19 Years Old.  
Note: The significant cluster is displayed on the study specific template using 
mricroGL®. 
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Cannabis-Associated Psychotic-Like Experiences Are Mediated by Developmental 
Changes in the Parahippocampal Gyrus 
RH=Cannabis-Associated PLEs Mediated by Parahippocampus 
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